ANGLE plc

Company Overview

Angle plc is developing and marketing diagnostic tests for cancer and fetal health. The company is developing a test for capturing very rare CTCs in the blood of cancer patients. The company’s main platform, Parsortix, captures very rare CTCs from the blood of cancer patients. Angle has identified ovarian, prostate and metastatic breast cancer as focus indications for its liquid biopsy platform.

The Parsortix platform uses microfluidics to capture and harvest the CTCs. The cells can be separated from other blood components because they are less deformable and are larger in size. This unique cell capture method provides several benefits. First, the Parsortix system can be applied to a wide range of cancer cell types and tumors, since it does not require cell surface markers for cell capture. Second, the cell capture method does not damage cells, so that intact undamaged cells are available for molecular analysis.

In breast cancer, Parsortix filed a De Novo submission to the FDA in September 2020 for use with metastatic breast cancer patients. The submission provides a data package that highlights Parsortix’s ability to harvest CTCs from metastatic breast cancer patient blood samples for downstream analysis. FDA clearance is expected to occur in the second quarter of 2021.

Angle has demonstrated that harvesting intact metastatic CTC clusters from blood samples has the potential to treat cancer patients with CTC clusters with repurposed FDA-approved drugs. In a paper in Cell in 2019,^[22] the research team described how these drugs break up CTC clusters and suppress metastasis, resulting in a near total elimination of metastasis in mouse models. This result is significant, as metastasis is responsible for more than 90% of all cancer-related deaths. Parsortix was cited in the research as the state-of-the art technology platform that enabled the isolation of CTC clusters for investigation. CTC cluster technology may be important for Angle to further differentiate itself from other CTC systems and cfDNA liquid biopsy approaches.

In ovarian cancer, Angle is developing a liquid biopsy test that could be used initially to triage patients who present with an abnormal pelvic mass to discriminate a benign pelvic mass condition from a malignant ovarian cancer. There is a 200-patient clinical verification study at the University of Rochester Wilmot Cancer Center begun in August 2019. This study should have data readout by the second half of 2021. Assuming that the data match the positive results from its earlier pre-study in confirmed ovarian cancer patients, Angle plans to launch a clinical assay for the detection of ovarian cancer in women with an abnormal pelvic mass as an LDT in 2022.

Financial Highlights (FY 2023)

Company's Business Segments

• Liquid Biopsy : The company provides cancer diagnostic product solutions, laboratory services, and advanced technology for biopharmaceutical and translational research.